Foveal LLP Independent Investment Research Foveal Research

The injectable IL23 class has been successful in treating a wide variety of inflammatory conditions such as psoriasis and inflammatory...

New data from MRK/MRNA cancer vaccine at ASCO last week continues to suggest a large underperformance of Keytruda control arm, along with...

As we highlighted in our February 23, 2020 report “Kisqali’s kiss of life“, NOVN's NATALEE trial of Kisqali demonstrated the broadest...

While ASCO 2023 does not offer much in updates for the three current lead contenders for anti-TIGIT combinations in non-small cell lung canc

In newly published data from Merck /Moderna’s PD1 + mRNA cancer vaccine trial, efficacy may be flattered by Keytruda alone control arm under

As expected, TIGIT addition to PD1 failed to beat chemo in second-line patients. The failure of Merck’s TIGIT+PD1 combo to beat second line

New data from Pfizer’s pneumococcal vaccine reveals inferiority to an important serotype 3 that makes up approximately one third of cases

We examine in detail, the prospects of five near term Pfizer pipeline assets, slated for the FDA over the next 3 years and find that there a

The first factor XIa clinical efficacy for stroke prevention was presented at the European Society of cardiology in Barcelona yesterday...

We undertake a detailed analysis of seven near term Roche pipeline assets, spanning Roche’s market leading positions in Non-Hodgkin lymphoma to breakthroughs for Duchene muscular dystrophy and find unique assets, but also successful competition